BACKGROUND: Strategies to improve bone health care in men receiving androgen deprivation therapy (ADT) are not consistently implemented. The authors conducted a phase 2 randomized controlled trial of 2 education-based models-of-care interventions to determine their feasibility and ability to improve bone health care. METHODS: A single-center parallel-group randomized controlled trial of men with prostate cancer who were receiving ADT was performed. Participants were randomized 1:1:1 to 1) a patient bone health pamphlet and brief recommendations for their family physician (BHP1FP); 2) a BHP and support from a bone health care coordinator (BHP1BHCC); or 3) usual care. The primary efficacy outcome was receipt of a bone mineral density (BMD) test within 6 months. Secondary efficacy outcomes included guideline-appropriate calcium and vitamin D use and bisphosphonate prescriptions for men at high fracture risk. Feasibility endpoints included recruitment, retention, satisfaction, contamination, and outcome capture. The main analysis used logistic regression with a 1-sided P of .10. The trial is registered at ClinicalTrials.gov (identifier NCT02043236). RESULTS: A total of 119 men were recruited. The BHP1BHCC strategy was associated with a greater percentage of men undergoing a BMD test compared with the usual-care group (78% vs 36%; P<.001). BMD ordering also was found to be increased with the BHP1FP strategy (58% vs 36%; P 5.047). Both strategies were associated with higher percentages of patients using calcium and vitamin D, but only the BHP1FP arm was statistically significant (P 5.039). No men were detected to be at high fracture risk. All but one feasibility endpoint was met. CONCLUSIONS: Educational strategies to improve bone health care appear feasible and are associated with improved BMD ordering in men receiving ADT. Cancer 2018;124:1132-40. V C 2017 American Cancer Society.
INTRODUCTION
Androgen deprivation therapy (ADT), which is widely used to treat prostate cancer, 1 is associated with significant skeletal side effects. Bone loss associated with the use of ADT is approximately 4% to 7% in the lumbar spine and hip in the first year, with smaller declines observed during subsequent years of ADT. 2 ADT also is associated with an excess relative risk of fractures of 50% to 70%, with absolute increases of 5% to 7% over 5 to 6 years of follow-up. 3, 4 Not only are fractures common, they represent a significant source of morbidity and excess mortality in men with prostate cancer. 5 Approximately 20% to 40% of older men with prostate cancer who initiate ADT already have osteoporosis, which usually is clinically silent before fracture. 6 However, osteoporosis can be detected with bone mineral density (BMD) testing, which also provides important information regarding future fracture risk and helps to guide subsequent preventive and treatment approaches. 7, 8 Guidelines and expert groups have recommended screening for osteoporosis at the start of ADT with BMD testing 8 , ensuring adequate calcium and vitamin D intake, 9 ,10 modifying lifestyle behaviors (smoking cessation, alcohol moderation, and regular exercise 9 , and prescribing bisphosphonates or denosumab for men with osteoporosis or who are at high fracture risk. 11 To properly understand a man's current bone health and future fracture risk and to tailor interventions based on fracture risk, measuring BMD with dual-energy x-ray absorptiometry is recommended for all men starting at least after 6 months of ADT. 8, 9 Validated algorithms to predict future fracture risk such as the Fracture Risk Assessment
Tool also have been recommended. 12 Calcium and vitamin D have been shown to reduce fractures in both women and men without prostate cancer. 9, 13 Bisphosphonates and denosumab are associated with improved BMD and reduced fracture risk in men with osteoporosis and men receiving ADT, respectively. 14 Whereas multiple interventions have been shown to improve bone health and reduce fractures in men receiving ADT, 11 significant gaps remain in the quality of bone health care. Rates of BMD testing in men receiving ADT remain low, even among men with prior fragility fracture or preexisting osteoporosis. 15 In other studies, the prescription of calcium (16%-19%), vitamin D (10%-19%), and bisphosphonates (5%-21%) among ADT users has been shown to be poor. 16, 17 Although to the best of our knowledge no largescale interventions have been studied to improve the quality of bone health care in men receiving ADT, significant evidence in women with osteoporosis supports several strategies, as summarized in a recent systematic review. 18 These include patient bone health care coordinators (BHCCs) 18, 19 and notifications to both physicians and patients, 20, 21 which have been shown to improve several aspects of bone health care. Importantly, improving the quality of bone health care is associated with a reduction in fractures. 22 However, the above studies have enrolled primarily women and to the best of our knowledge no randomized trial to date has included men receiving ADT. Therefore, we conducted a 3-arm phase 2 randomized controlled trial (RCT) to examine 2 potential education-based models of care to improve bone health care in men receiving ADT. Our specific objectives were: 1) to assess the feasibility of conducting a larger RCT by documenting recruitment rate, adherence, retention, patient and physician satisfaction, outcome capture, and contamination; and 2) to obtain a preliminary estimate of efficacy for the interventions on receipt of a BMD test within 6 months of randomization. We also examined whether either strategy was associated with the receipt of guideline-appropriate doses of calcium and vitamin D, lifestyle changes, and the use of bisphosphonates/denosumab.
MATERIALS AND METHODS

Study Design
The current study was a single-center, parallel, 3-arm RCT. Outcome assessors were not blinded to intervention assignment. Ethics approval was received from the institutional research ethics board and all men provided written informed consent. The trial was registered at ClinicalTrials.gov (identifier NCT02043236).
Patient Inclusion/Exclusion Criteria
Men aged 50 years who were initiating or continuing ADT for a minimum of 6 months for nonmetastatic or castration-sensitive metastatic prostate cancer were eligible. Other inclusion criteria included: 1) a life expectancy > 6 months; 2) no BMD test or osteoporosis clinic visit within the past 2 years; and 3) fluency in English. Men who were taking calcium, vitamin D, a bisphosphonate, or denosumab at baseline were eligible.
Recruitment and Randomization
Men were recruited from radiation oncology, urology, and medical oncology clinics at the Princess Margaret Cancer Centre (PM), a tertiary care facility. After obtaining consent, men were randomized in a 1:1:1 ratio using sealed, opaque, sequentially numbered envelopes generated by the study statistician. Randomization was stratified by duration of prior ADT use: < 1 year versus 1 year. Study participants received a 10-page customized bone health pamphlet (BHP) (see Supporting Information) that we had created and pilot tested previously. 23 The pamphlet covered the bone side effects of ADT, the importance of BMD measurement, appropriate doses and sources of calcium and vitamin D, lifestyle modifications to optimize bone health, and fracture risk prediction. A brief customized letter was sent to the patient's family physician (FP), with specific advice and recommendations for BMD screening and bone health care, along with a pocket card for current recommendations from Osteoporosis Canada and a copy of the patient BHP (see Supporting Information). This letter was adapted from 2 prior successful trials in women with osteoporosis. 19, 21 Both the BHP and letter included a list of additional resources. The same written patient material as was used in strategy 1 was used in strategy 2, along with a BHCC who contacted the patient by telephone or arranged an in-person visit at PM if preferred by the patient. The BHCC went through the educational material with the patient using principles of adult education and chronic disease selfmanagement. 24, 25 The BHCC followed up with the patient at least twice (generally by telephone) over 3 months to facilitate behavioral changes and BMD ordering. The BHCC also contacted the patient's FP by telephone or fax to help facilitate BMD testing. Additional details are provided in the Supporting Information.
Interventions
Control Group
The control group received no specific recommendations or interventions from study staff. Prostate cancer clinicians were free to provide usual care. During the period of study recruitment, there was no systematic approach to bone health care at PM and no written material specific to men receiving ADT. At the end of 6 months, control group participants were offered a referral to the osteoporosis clinic at PM.
Outcomes
The primary feasibility outcomes were as follows: 1) recruitment; 2) adherence; 3) retention; 4) patient/physician satisfaction; 5) outcome capture; and 6) contamination. These are defined in Table 1 . [1] [2] [3] [4] [5] [6] The primary clinical Abbreviation: WHO, World Health Organization. All outcomes were assessed 6 months after randomization.
outcome was receipt of BMD within 6 months of randomization. Secondary clinical outcomes were as follows: 1) receipt of guideline-appropriate doses of calcium and vitamin D; 2) physician recommendation/prescription of a bisphosphonate or denosumab in patients with osteoporosis or a high fracture risk (based on a validated algorithm); and 3) changes in lifestyle factors (eg, alcohol moderation, smoking cessation, physical activity).
Details regarding definitions and ascertainment of each of the above outcomes are shown in Table 1 .
1-6
Sample Size
Following standard guidelines for phase 2 RCTs, 26 we aimed for 30 patients per arm with a 10% dropout rate (100 patients in total) to provide reasonable precision for feasibility outcomes (68% around estimates with a number of 100). For our primary clinical outcome, we aimed to detect at least a 20% improvement in BMD testing with a 1-sided a of .10 and b of .20 in pairwise comparisons between each treatment arm versus usual care. This approach was chosen to improve power to identify promising interventions to move forward into a phase 3 RCT while recognizing that neither strategy was likely to worsen BMD testing rates. 27 
Statistical Analyses
Baseline patient characteristics were summarized. All feasibility outcomes were analyzed descriptively with means or percentages as appropriate along with 95% confidence intervals (95% CIs). For receipt of BMD, logistic regression was used adjusting for prior BMD test receipt, whereas for secondary clinical outcomes, comparisons of each treatment group were made with the control group using a difference of proportions approach. This allowed us to control for the percentage of individuals who already were meeting the target for a given outcome (eg, calcium intake) at baseline. Analyses were repeated using a generalized estimating equation approach. No statistical adjustment for multiple comparisons was performed, recognizing a greater risk of a poorly performing strategy going forward but also the limited "risk" of each intervention and the desire to minimize false-negative results in a phase 2 study. 
Criteria to Move Forward
We defined a priori criteria for both feasibility and efficacy outcomes to move forward with a phase 3 RCT. For feasibility outcomes, this consisted of the recruitment of at least 60% of eligible patients, adherence of at least 70%, study retention of 80%, mean satisfaction scores of 4/5 among patients and physicians, and 80% outcome capture. For efficacy outcomes, we required a 20% increase in the rate of BMD testing or a 20% increase in at least 2 of 3 secondary clinical outcomes compared with controls. This difference is considered clinically important based on expert input and prior literature.
1,2
RESULTS
A total of 254 potentially eligible men aged 50 years who were receiving ADT were identified between December 2013 and November 2014, 80 of whom (31.5%) were ineligible for reasons shown in Figure 1 . Of the 174 remaining patients (68.5%), 55 declined and 119 consented and were randomized (68.4% recruitment rate). Three men subsequently were found to be ineligible, 1 man withdrew, and 2 men were lost to follow-up. This left 112 men for analysis: 36 in the BHP1FP arm, 40 in the BHP1BHCC arm, and 36 in the usual-care arm. Details are shown in Figure 1 .
Baseline characteristics were well balanced across the intervention arms (see Supporting Information Table 1 ).
Feasibility Outcomes
The recruitment rate exceeded our target of 60%. Participant retention and satisfaction were found to be high in all 3 groups. Approximately 80% of the prostate cancer specialists of participants in the 2 intervention arms also were satisfied or very satisfied with the study. Outcome capture was high, and contamination was low (Table 2) . However, responses from primary care physicians were received from only 22 of 40 physicians, of whom only 12 (55%) recalled receiving written recommendations. Moreover, only 3 of 11 found the written recommendations to be helpful. Other than primary care physicians' responses and satisfaction, all 6 feasibility outcomes met targets (Table 2) .
Clinical Outcomes
A total of 23 (57.5%), 29 (80.6%), and 13 (36.1%) men, respectively, in the BHP1FP arm, BHP1BHCC arm, and usual-care arm underwent a BMD test within 6 months of randomization. In multivariable models, being assigned to the BHP1BHCC arm was associated with a greater likelihood of undergoing a BMD test (odds ratio [OR], 8.00; 90% CI, 3.11-20.6) than usual care (Table 2 ) (see Supporting Information Table 2 ). Similarly, being assigned to the BHP1FP arm was associated with increased odds of undergoing a BMD test (OR, 2.70; 90% CI, 1.19-6.15).
In the BHP1FP arm, the difference from baseline to 6 months in the percentage of participants meeting guideline-appropriate calcium intake was 15.6% greater than that of patients in the usual-care arm (1-sided P 5 .0386). In contrast, the BHP1BHCC arm was associated with an increase of 5.6% in guideline-appropriate (Table 3) . 3, 4 No participants were newly detected as being at high fracture risk during the intervention phase, although 5 men were known to be at high fracture risk at the time of study entry. None of the 5 men was prescribed a bisphosphonate or denosumab (Table 3) . 3, 4 Few men were smoking or consuming excess alcohol in all 3 groups, and between-group differences were not found to be statistically significant (Table 3) . 3, 4 DISCUSSION Almost 1 in 2 men with prostate cancer will receive ADT at some point after diagnosis, 1 and as a result be at risk of fracture; effective strategies to minimize this risk exist but to our knowledge implementation remains suboptimal. 17 We performed a phase 2 RCT of 2 education-based models of care designed to improve bone health quality of care in men receiving ADT.
The current phase 2 RCT had 2 main goals. The first goal was to determine whether such a trial is feasible to conduct. In this regard, all of our feasibility targets but 1 were met. Before embarking on a larger trial, feedback from primary care physicians regarding our customized letter will be required to ensure it is clear and helpful, and greater attention will need to be paid to ensuring the written information is received in a timely manner (eg, with follow-up telephone calls or acknowledgment postcards).
The second goal was to determine whether either or both educational strategies was/were associated with an improvement in BMD ordering and other bone health strategies. We found that both strategies were associated with improved rates of BMD ordering, and that the BHP1FP strategy was associated with improvements in calcium intake, whereas neither strategy improved other lifestyle factors or the use of vitamin D compared with usual care. No men were newly detected as being at high fracture risk.
Although there was no appreciable impact on vitamin D intake, this may be because the majority of men in all 3 groups already were meeting guideline targets at baseline. For other lifestyle changes such as smoking cessation and alcohol moderation, intervention effects could not be reliably ascertained for these outcomes due to the low frequency of targetable behaviors. It is interesting to note that we did not detect any new men with a high fracture risk. Future studies should evaluate not only whether BMD ordering is improved but also whether antiresorptive agents are prescribed to men at high fracture risk because this maneuver has been well established to reduce fractures. 28 Larger samples also will allow for the more precise determination of impact on bone-relevant lifestyle factors.
To our knowledge, the current study is the first randomized intervention to target bone health quality of care in men receiving ADT. One pre-post pilot study of a multicomponent intervention in 148 men receiving ADT, consisting of patient education and a personalized fracture risk assessment letter, suggested improvements in osteoporosis knowledge and vitamin D intake (24%), but not calcium intake. 29 However, all enrolled men had undergone a BMD test at baseline. In comparison, various strategies similar to ours have been shown to improve rates of investigation (including BMD testing) by a median of 43% in adults with fragility fracture whereas medication use was lower at 22%. 18 Although the current study has several strengths, including being to the best of our knowledge the first randomized intervention and featuring relevant, low-cost interventions, several limitations also must be kept in mind. Our modest sample size did not allow us to examine impact on lifestyle factors such as smoking and alcohol. The participants in the current study were relatively well educated and had limited comorbidity. It is interesting to note that none of the current study participants was found to have high fracture risk, and therefore effects on the use of antiresorptive therapy could not be determined. The current study was situated in a single academic center with an interest in the side effects of ADT on bone health; thus, it will be important to test the intervention in other settings and recruit a broader population at higher risk of fracture. Outcome assessors were not blinded, although our primary efficacy outcome (receipt of a BMD test) was verified. Finally, physician feedback was sought at the end of the intervention for each participant (ie, 6 months); the associated recall bias likely partly explained the responses of the primary care physicians.
Importantly, the treatments for prostate cancer are changing rapidly, with a shortening of ADT schedules or its omission in some scenarios and the earlier use of androgen axis-targeted agents and chemotherapy in the metastatic setting. However, to the best of our knowledge, none of these agents is known to ameliorate the deleterious effects of ADT on bone, although medication complexity and burden will need to be considered.
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